GenWay Biotech launches multiple biomarker test for myocardial infarction

Testing for multiple biomarkers can improve the sensitivity and accuracy of predictive tests, and GenWay Biotech has created and launched a three-biomarker test--called PREvent--which is designed to help primary care physicians and cardiologists to predict the near term (two- to three-year) risk of heart attack in patients with coronary artery disease. The company presented data on the test at the American Heart Association Scientific Sessions 2011 (AHA), in Orlando, Florida. In a study of around 3000 people with suspected or confirmed coronary artery disease, the test identified the top 10% of patients with confirmed coronary artery disease who were six-and-a-half times more likely to have a heart attack within three years, and was 12 times more powerful than the single biomarker CRP. Release | Abstract

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.